<DOC>
	<DOCNO>NCT00983268</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high energy x-ray kill tumor cell . Giving capecitabine vorinostat together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vorinostat give together capecitabine radiation therapy treat patient nonmetastatic pancreatic cancer .</brief_summary>
	<brief_title>Capecitabine , Vorinostat , Radiation Therapy Treating Patients With Nonmetastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose vorinostat give combination capecitabine high-dose hypofractionated radiotherapy patient nonmetastatic pancreatic cancer . Secondary - Determine safety side effect profile regimen patient . - Determine response rate patient treat regimen . Correlative - Compare pre- post-treatment whole-cell HDAC-activity level peripheral blood mononuclear cell sample . - Assess chromatin structure DNA damage surgical tumor tissue sample . - Assess proliferation apoptosis vivo image . OUTLINE : This dose-escalation study vorinostat . Patients receive oral capecitabine twice daily undergo high-dose hypofractionated radiotherapy daily day 1-5 8-12 . Patients also receive oral vorinostat daily day 1-5 , 8-12 , 15-19 , 22-26 absence disease progression unacceptable toxicity . Patients evaluate surgery within 6 week completion chemoradiotherapy . Patients resectable disease proceed surgery . Patients unresectable disease may receive oral vorinostat daily oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect periodically correlative laboratory study . Patients also undergo diffusion-weighted MRI analysis vivo tumor cellularity . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must histologically confirm pancreatic periampullary cancer . Patient must &gt; 18 year age . Patient may resectable , borderline resectable , unresectable locally advanced determine radiographic examination consultation surgical oncologist . Patient must Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . Female patient childbearing potential must willing use birth control . The 2 birth control method either 2 barrier method barrier method plus hormonal method prevent pregnancy , use throughout study start visit 1 . The following consider adequate barrier method contraception : diaphragm , condom ( partner ) sponge . Other method contraception copper intrauterine device spermicide may use . Appropriate hormonal contraceptive include register marketed contraceptive agent contains estrogen and/or progestational agent ( include oral , subcutaneous , intrauterine , intramuscular agent ) .Female patient childbearing potential negative serum pregnancy test βhCG within 7 day prior receive first dose vorinostat . Male patient agree use adequate method contraception duration study . Patient life expectancy least 12 week Patient must adequate organ function indicate follow laboratory value : Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥100,000 / mcL Hemoglobin ≥ 9 g/dL Coagulation Prothrombin Time INR ≤1.5x upper limit normal ( ULN ) unless receive therapeutic anticoagulation Partial thromboplastin time ( PTT ) ≤1.2 time ULN unless patient receive therapeutic anticoagulation . K level Normal limit Mg level Normal limit Calculated creatinine *clearance ≥20 mL/min Serum total bilirubin ≤ 1.5 X ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN Alkaline Phosphatase ≤ 2.5 X ULN * Creatinine clearance calculate per institutional standard . Patient must capable understand comply study protocol able give inform consent . Measurable disease eligibility requirement . Prior chemotherapy pancreatic periampullary cancer . Prior radiation area within plan radiation field . All patient history prior radiation area must approve PI . Evidence distant metastasis image . History hypersensitivity fluoropyrimidines HDACs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>periampullary adenocarcinoma</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>